200,000 Shares in Compass Pathways PLC Sponsored ADR $CMPS Bought by Vivo Capital LLC

Vivo Capital LLC bought a new stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the first quarter, HoldingsChannel reports. The fund bought 200,000 shares of the company’s stock, valued at approximately $1,106,000.

A number of other large investors have also added to or reduced their stakes in the company. RTW Investments LP lifted its stake in Compass Pathways by 0.6% during the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock worth $60,426,000 after purchasing an additional 50,000 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in shares of Compass Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after purchasing an additional 1,350,698 shares in the last quarter. Millennium Management LLC increased its position in shares of Compass Pathways by 39.9% during the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after purchasing an additional 774,090 shares during the last quarter. Toronto Dominion Bank increased its position in shares of Compass Pathways by 152.9% during the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after purchasing an additional 1,529,013 shares during the last quarter. Finally, ARK Investment Management LLC raised its holdings in shares of Compass Pathways by 1.6% during the 4th quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock valued at $14,876,000 after buying an additional 34,894 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Analysts Set New Price Targets

CMPS has been the subject of a number of recent research reports. Wolfe Research restated an “outperform” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. BTIG Research increased their price target on shares of Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research note on Friday, July 17th. Morgan Stanley restated an “overweight” rating and issued a $17.00 price objective on shares of Compass Pathways in a report on Tuesday, July 7th. Finally, UBS Group set a $18.00 price objective on shares of Compass Pathways in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Compass Pathways presently has a consensus rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Price Performance

CMPS opened at $11.57 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. The stock’s 50 day simple moving average is $12.54 and its 200 day simple moving average is $9.13. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -3.67 and a beta of 2.47. Compass Pathways PLC Sponsored ADR has a 1 year low of $3.92 and a 1 year high of $15.40.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. As a group, analysts predict that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.